DODAP manufacturers
- DODAP
-
- $37.00 / 5mg
-
2025-12-05
- CAS:127512-29-2
- Min. Order:
- Purity: 98.70%
- Supply Ability: 10g
- DODAP
-
- $0.00 / 1g
-
2025-09-10
- CAS:127512-29-2
- Min. Order: 1g
- Purity: 98%
- Supply Ability: 1g/bottle , 10g/bottle, 100g/bottle
- DODAP
-
- $0.00 / 1KG
-
2025-06-27
- CAS:127512-29-2
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 500000kg
|
| | DODAP Chemical Properties |
| Boiling point | 670.1±55.0 °C(Predicted) | | density | 0.916±0.06 g/cm3(Predicted) | | storage temp. | -20°C Freezer, Under Inert Atmosphere | | solubility | Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly) | | form | Oil | | pka | 8.02±0.28(Predicted) | | color | Colourless to Light Yellow | | Stability: | Light Sensitive; Hydroscopic; Store at -15 to -25°C | | InChIKey | NYDLOCKCVISJKK-WRBBJXAJSA-N | | SMILES | C(OC(=O)CCCCCCC/C=C\CCCCCCCC)(CN(C)C)COC(=O)CCCCCCC/C=C\CCCCCCCC |
| | DODAP Usage And Synthesis |
| Description | DODAP (18:1) is an ionizable cationic lipid with lower cytotoxicity and high transfection efficiency. DODAP is neutral at physiological pH, but acquires a positive charge inside the endosome due to the protonation of free amines when pH is lower than its pKa (<7). | | Chemical Properties | Light Yellow Oil | | Uses | DODAP is a cationic lipid utilized as the lipid component in liposomes (pKa = 5.59 in TNS binding tests). DODAP is employed for encapsulating siRNA and delivering immunostimulated chemotherapeutic agents both in vitro and in vivo. DODAP holds great promise for research in vaccines and inflammation[1][2][3][4][5]. | | in vivo | In vitro potency of DODAP (100 μg/mL, i.v., i.m., 4h) strongly predicts in vivo potency for intramuscular administration but not for intravascular administration in female Balb/c mice[1]. | Animal Model: | female Balb/c mice[1] | | Dosage: | 100 μg/mL | | Administration: | Intravenous injection (i.v.), Intramuscular injection (i.m.),4 h | | Result: | Treatment resulted that a less negatively charged DODAP was more efficient in vitro and in vivo intramuscular injection, while for Intravenous injection administration, a more negative DODAP that was passively targeted through Apo-E absorption was more efficient for hepatocyte targeting. |
| | References | [1] Carrasco MJ, et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun Biol. 2021 Aug 11;4(1):956. DOI:10.1038/s42003-021-02441-2
[2] Dabbas S, et al. Importance of the liposomal cationic lipid content and type in tumor vascular targeting: physicochemical characterization and in vitro studies using human primary and transformed endothelial cells. Endothelium. 2008;15(4):189-201. DOI:10.1080/10623320802228583
[3] Hamzah J, et al. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. J Immunol. 2009;183(2):1091-1098. DOI:10.4049/jimmunol.0900736
[4] Liu Q, et al. Biotinylated cyclen-contained cationic lipids as non-viral gene delivery vectors. Chem Biol Drug Des. 2013;82(4):376-383. DOI:10.1111/cbdd.12159
[5] Mendon?a LS, et al. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug Chem. 2010 Jan;21(1):157-68. DOI:10.1021/bc9004365 |
| | DODAP Preparation Products And Raw materials |
|